Compounds > mebikar
Page last updated: 2024-11-07

mebikar

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mebikar: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122282
CHEMBL ID3707390
CHEBI ID136038
SCHEMBL ID1465373
SCHEMBL ID15685069
SCHEMBL ID14037060
MeSH IDM0065674

Synonyms (50)

Synonym
10095-06-4
adaptol
mebicar
mebikar
2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo-(3.3.0)-octan-3,7-dione
2,4,6,8-tetramethyl-2,4,6,8-tetraazobicyclo(3.3.0)octane-3,7-dione
tetrahydro-1,3,4,6-tetramethylimidazo(4,5-d)imidazole-2,5(1h,3h)-dione
imidazo(4,5-d)imidazole-2,5(1h,3h)-dione, tetrahydro-1,3,4,6-tetramethyl-
2,4,6,8-tetramethyl-2,4,6,8-tetraazobizykl(3,3,0)oktandion-3,7 [german]
CHEMDIV1_025094
STK022918
1,3,4,6-tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1h,3h)-dione
CHEBI:136038
xiuusfjtjxfngh-uhfffaoysa-
inchi=1/c8h14n4o2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6h,1-4h3
AKOS000487401
2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-dione, 2,4,6,8-tetramethyl-
HMS658E14
1,3,4,6-tetramethyl-3a,6a-dihydroimidazo[4,5-d]imidazole-2,5-dione
SCHEMBL1465373
1,3,4,6-tetramethyl-1,3,4,6,3a,6a-hexahydro-1,3,4,6-tetraazapentalene-2,5-dion e
FT-0684250
unii-55fe6npg89
2,4,6,8-tetramethyl-2,4,6,8-tetraazobizykl(3,3,0)oktandion-3,7
55fe6npg89 ,
D10508
glycoluril, 1,3,4,6-tetramethyl-
temgicoluril
tetramethylglycoluril
temgicoluril [who-dd]
imidazo(4,5-d)imidazole-2,5(1h,3h)-dione, tetrahydro-1,3,4,6-tetramethyl-, cis-
temgicoluril [inn]
106780-29-4
CHEMBL3707390
SCHEMBL15685069
1,3,4,6-tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1h,3h)-dione #
XIUUSFJTJXFNGH-UHFFFAOYSA-N
imidazo[4,5-d]imidazole-2,5-(1h,3h)dione, tetrahydro-1,3,4,6-tetramethyl-
1,3,4,6-tetramethyltetrahydroimidazo[4,5-d]-imidazole-2,5(1h,3h)-dione
SCHEMBL14037060
DTXSID60143588
imidazo[4,5-d]imidazole-2,5(1h,3h)-dione, tetrahydro-1,3,4,6-tetramethyl-
mfcd00184215
2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-dione
Q4286560
DB13522
1,3,4,6-tetramethyl octahydroimidazo[4,5-d]imidazolidine-2,5-dione
1,3,4,6-tetramethyl-octahydro-[1,3]diazolo[4,5-d]imidazole-2,5-dione
LS-04732
CS-0213579

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Twenty-two patients admitted to the narcological clinic of an industrial enterprise were examined for the clinical effect and pharmacokinetic parameters after intake of a single dose of a Soviet psychotropic drug mebicar."( [Clinical pharmacokinetics of mebikar].
Berliand, AS; Knizhnik, AZ; Lapin, KV; Serov, NV; Treskov, VG, )		0.42

Dosage Studied

ExcerptRelevanceReference
"The authors review the principles of calculating the optimal dosage regimens of mebicar used in the treatment of borderline psychopathological abnormalities in alcoholics."( [Clinical pharmacokinetics of mebikar. Computation of individual dosage regimens].
Berliand, AS; Knizhnik, AZ; Serov, NV; Sidorov, AA; Treskov, VG, )		0.42
" The correlation of the pharmacodynamic and pharmacokinetic data can be used for the choice of minimal effective concentrations applied in further calculations of individual dosage regimens."( [Clinical pharmacokinetics of mebikar].
Berliand, AS; Knizhnik, AZ; Lapin, KV; Serov, NV; Treskov, VG, )		0.42
" Antihypoxic effect of the drug manifests within a wide dosage range (100-1000 mg/kg) and compares favourably with the effect of sodium hydroxybutyrate."( [Effect of mebikar on the state of animals under extreme conditions].
Kamburg, RA; Kirshin, SV; Zimakova, IE, )		0.52
" The use of adaptol in dosage 500 mg 2 times daily during one month resulted in the decrease of hyperactivity and impulsivity and did not exert any influence on attention and reaction time."( [Adaptol in the treatment of ADHD].
Anisimova, TI; Chutko, LS; Iakovenko, EA; Nikishena, IS; Sergeev, AV; Surushkina, SIu, 2009)		0.35
" An evaluation of the efficacy of the drug Adaptol used in daily dosage 1500 mg during 8 weeks in the treatment of these patients revealed its high efficacy (the improvement was seen in 74% of cases) confirmed by the data of clinical and psychological studies."( [Neurocirculatory asthenia: psychoautonomic features and treatment possibilities].
Chutko, LS; Frolova, NL; Surushkina, SIu, 2012)		0.38
"There is a presents a clinical case of idiopathic ventricular arrhythmia developing in a 27-year-old young woman with anxiety neurosis successfully treated with the anxiolytic Adaptol used in daily dosage 1500 mg during a month."( [A case of effective psychogenic ventricular arrhythmia treatment with the anxiolytic Adaptol].
Il'ina, DIu; Treshkur, TV; Tsurinova, EA, 2013)		0.39
" This study evaluated the efficacy and safety of adaptol in dosage 1500 mg daily during 8 weeks in the treatment of this group of patients."( [Attention deficit syndrome in adults: clinical, psychophysiological features and treatment].
Anisimova, TI; Chutko, LS; Iakovenko, EA; Nikishena, IS; Surushkina, SIu, 2013)		0.39
" Patients of the first group received adaptol in dosage 1000 mg daily and patients of the second group received noofen in dosage 500 mg daily."( [Asthenic disorders in children and their differentiated treatment].
Anisimova, TI; Bondarchuk, IL; Chutko, LS; Iakovenko, EA; Nikishena, IS; Sergeev, AV; Surushkina, SI, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidinoneAn imidazolidine containing one or more oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (30.00)18.7374
1990's2 (5.00)18.2507
2000's1 (2.50)29.6817
2010's24 (60.00)24.3611
2020's1 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.90 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index40.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (27.87%)5.53%
Reviews2 (3.28%)6.00%
Case Studies3 (4.92%)4.05%
Observational0 (0.00%)0.25%
Other39 (63.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		4.6532amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		2.4920carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
pantogab
pantogab: RN given refers to cpd without isomeric designation; synonym hopantenic acid refers to (R)-isomer; synonym pantogam refers to Ca salt (2:1), ((R)-isomer		3.4411
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		2.3620benzodiazepine
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		3.08501,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		1.9610ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		2.3620organic molecular entity
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.07103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
aminopyrine
Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.		1.9610pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		1.9610adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		1.9610adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.610arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
pantothenic acid
Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.		3.4411pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		1.9910dialdehydebiomarker
4-amino-3-phenylbutyric acid
4-amino-3-phenylbutyric acid: phenyl deriv of GABA; RN given refers to cpd without isomeric designation; structure		3.7921organonitrogen compound;
organooxygen compound
phenazepam
[no description available]		1.9610
trimeperidine
Promedol: A narcotic analgesic similar to MEPERIDINE; it exists in four stereoisomers, two of which, the beta (isopromedol) and the gamma (trimeperidine) are active.		2.3720
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.07109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ginsenoside rg1
[no description available]		2.171012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		neuroprotective agent;
pro-angiogenic agent
dipyrone
Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.		1.9610organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
amiridine
amiridine: do not confuse with neuromedin		3.4711aminoquinoline
lithium
Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.		2.3620alkali metal atom
ginsenosides
ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.		2.1710
sodium oxybate
Sodium Oxybate: The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease
[description not available]		02.610
Blood Pressure, High
[description not available]		05.3343
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		05.3343
Anxiety Neuroses
[description not available]		06.3685
Anxiety Disorders
Persistent and disabling ANXIETY.		06.3685
Extrasystole, Ventricular
[description not available]		03.4611
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		05.6954
Arrhythmia
[description not available]		02.0810
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.0810
Acute Brain Injuries
[description not available]		03.4711
Cerebral Ischemia
[description not available]		03.4711
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		03.4711
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		03.4711
ADDH
[description not available]		04.1431
Symptom Cluster
[description not available]		03.8721
Attention Deficit Disorder with Hyperactivity
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)		16.1431
Syndrome
A characteristic symptom complex.		03.8721
ANS (Autonomic Nervous System) Diseases
[description not available]		05.0733
Cardiovascular Stroke
[description not available]		03.4711
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		03.4711
Eczema, Atopic
[description not available]		02.110
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		02.110
Lassitude
[description not available]		03.4811
Bodily Distress Disorder
[description not available]		04.4222
Asthenia
Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.		04.4222
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		03.4811
Ache
[description not available]		02.1110
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.1110
Burnout, Professional
An excessive stress reaction to one's occupational or professional environment. It may be characterized by feelings of emotional and physical exhaustion, coupled with a sense of frustration and failure.		03.4411
Cervicogenic Headache
[description not available]		03.4511
Adult-Onset Dystonias
[description not available]		03.4511
Dystonic Disorders
Acquired and inherited conditions that feature DYSTONIA as a primary manifestation of disease. These disorders are generally divided into generalized dystonias (e.g., dystonia musculorum deformans) and focal dystonias (e.g., writer's cramp). They are also classified by patterns of inheritance and by age of onset.		03.4511
Brain Vascular Disorders
[description not available]		03.4511
Indigestion
[description not available]		03.4511
Cerebrovascular Disorders
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.		03.4511
Dyspepsia
Impaired digestion, especially after eating.		03.4511
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4220
Anasarca
[description not available]		02.0610
Foot Diseases
Anatomical and functional disorders affecting the foot.		02.0610
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0610
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		04.4222
Claustrophobia
[description not available]		04.4222
Phobic Disorders
Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.		04.4222
Psychophysiologic Disorders
A group of disorders characterized by physical symptoms that are affected by emotional factors and involve a single organ system, usually under AUTONOMIC NERVOUS SYSTEM control. (American Psychiatric Glossary, 1988)		02.0710
Acute Bacterial Prostatitis
[description not available]		02.0710
Prostatitis
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.		02.0710
Chronic Illness
[description not available]		02.0710
Childhood Tic Disorders
[description not available]		02.0710
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0710
Cardiac Neurosis
[description not available]		03.4611
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		01.9510
Alcohol Abuse
[description not available]		01.9610
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		01.9610
Shock, Traumatic
Shock produced as a result of trauma.		02.8840
Neuroses
[description not available]		01.9610
Neurotic Disorders
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.		01.9610
Absence Seizure
[description not available]		01.9610
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9610
Allergic Cutaneous Angiitis
[description not available]		01.9810
Angioneurotic Edema
[description not available]		01.9810
Allergy, Drug
[description not available]		01.9810
Atopic Hypersensitivity
[description not available]		01.9810
Disease, Pulmonary
[description not available]		01.9810
Angioedema
Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.		01.9810
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		01.9810
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9810
Lung Diseases
Pathological processes involving any part of the LUNG.		01.9810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Bradykinesia
[description not available]		01.9910
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		01.9910
Cardiomyopathies, Primary
[description not available]		01.9710
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		01.9710
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		01.9710
Hemorrhagic Shock
[description not available]		01.9610